We would love to hear your thoughts about our site and services, please take our survey here.
https://www.investorschronicle.co.uk/tips-ideas/2019/10/03/chi-med-rocked-as-major-shareholder-drops-stake/
IC View
Chi-Med hasn’t set out to revolutionise cancer treatment, it has sensibly built a portfolio of drugs that can treat previously underserved offshoots of the disease. It’s a strategy that has earned it global recognition in the form of partnerships with leading drugs companies. Although we appreciate this remains a speculative, high-risk investment that may continue to be rocked by political and market turbulence, for those looking for investment in the drug development space, we don’t think there is a better candidate in the UK. Buy at 292p.
Price was as low as 655 yesterday morning. Unfortunately I didn't have any funds to top up.
Not at all surprised this is happening.
The Board of Hutchison China Meditech has announced its intention to subdivide each existing ordinary share into 10 new ordinary shares, subject to shareholder approval at an Extraordinary General Meeting to be held on Wednesday 29 May 2019.
Shareholders as at the close of business on 29 May 2019 will have their holding subdivided, receiving 10 new shares in place of every share previously held. The new subdivided shares are expected on Thursday 30 May 2019.
Perhaps this is the reason for it. https://www.sharesmagazine.co.uk/news/market/6406502/Broker-Forecast-Liberum-Capital-issues-a-broker-note-on-AB-Dynamics-Plc